High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma

Abstract

The C-reactive protein-to-albumin ratio (CAR) has not been assessed in diffuse large B cell lymphoma (DLBCL, the most common non-Hodgkin lymphoma). This retrospective study evaluated the prognostic value of CAR in 186 DLBCL patients. A CAR value of 0.158 was selected as the most discriminative cut-off for identifying patients with high CAR values (73/141 patients, 51.8%). During a median follow-up of 32.5 months, the high CAR group had significantly poorer complete response to induction therapy (64.4% vs. 92.6%; p<0.001), 3-year overall survival (OS) (68.3% vs. 96.2%; p<0.0001), and 3-year progression-free survival (PFS) (53.5% vs. 88.0%; p<0.0001). After adjusting for the International Prognostic Index components, a high CAR value independently predicted poor OS (HR: 6.02, 95% CI 1.19-30.38; p=0.030) and PFS (HR: 3.62, 95% CI 1.40-9.36; p=0.008). In an independent validation cohort (n=50), patients with CAR>0.158 also showed worse 3-year OS (47.9% vs. 87.2%, p=0.0035) and 3-year PFS (36.1% vs. 82.1%, p=0.0011). A high CAR remained significantly associated with poor outcomes for>60-year-old patients (OS: p=0.0038, PFS: p=0.0015) and younger patients (OS: p=0.0041, PFS: p=0.0044). Among older patients, a high CAR value also predicted non-relapse mortality (p=0.035). Therefore, the CAR might complement the International Prognostic Index in DLBCL cases.